Located in the University Research Park in Salt Lake City, Utah, Alucent Biomedical is a privately held biotechnology company founded to transform the way vascular disease is treated, naturally.
Alucent Biomedical is developing a potential breakthrough combination drug-device therapy for vascular disease called Natural Vascular Scaffolding™ (NVS). NVS is a first-of-a-kind combination drug-device therapy designed to assist the body in naturally opening and maintaining arterial patency.
The first indication the company is seeking for NVS is the treatment of peripheral artery disease (PAD).
NVS was developed by Alumend, LLC, a research and development company owned by Avera Health.
James Corbett has more than 30 years of leadership experience in the medical device field. Currently chief executive officer of CathWorks Ltd., he previously he served as chief executive officer and president of Alphatec Spine, Inc., and president of Alphatec Holdings, Inc.
Myles Greenberg, M.D.
President & CEO
Dr. Myles Greenberg comes to Alucent Biomedical with more than 20 years of experience in growing healthcare, medical technology and life sciences firms as an entrepreneur, operating executive, board member, clinician and investor.
Vice President of Regulatory Affairs
Bruce Krattenmaker has deep experience leading global regulatory and clinical affairs for start-up and large medical device companies. Krattenmaker has a legacy of new and creative approaches to gaining swift approvals for medical device technology.
Katalin Kauser, MD, PhD, DSc
Vice President, Head of Biology
Dr. Katalin Kauser joined Alucent Biomedical after 20 years of experience in the pharmaceutical industry, specializing in cardiovascular research aimed at developing innovative therapeutics for treating ischemic cardiac disease, atherosclerosis, systemic hypertension, chronic kidney disease, pulmonary hypertension, pulmonary fibrosis, heart failure, and hematologic disorders.
Vice President of Clinical Affairs
Julie Logan has more than 20 years of experience in the cardiovascular field conducting clinical trials, developing cutting-edge cardiovascular products and performing complex coronary, vascular and structural interventions.
Vice President of Finance and Administration
Scott Mayfield brings more than 20 years of experience managing finance, accounting and human resources for growing life science companies funded by venture capital, private equity and angel investors.
Jane Ren, Ph.D.
Vice President, Research & Development and Chief Technology Officer
Dr. Jane Ren joined Alucent Biomedical from CeloNova BioSciences where she held the position of chief technology officer. During her eight year tenure there, she led cross-functional teams for both interventional oncology and interventional cardiology platforms, throughout all phases of commercialization.
Krishna Rocha-Singh, M.D., FACC
Chief Medical Advisor
Dr. Krishna Rocha-Singh is chief scientific officer for Prairie Heart Institute at St. John’s Hospital in Springfield, Ill. In addition, he is a current co-founding board member of Vascular InterVentional Advances (VIVA), a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research.
Ron Utecht, Ph.D.
Dr. Ron Utecht oversees the scientific direction for Alumend, the technology development company responsible for the inception of the NVS Therapy. He has more than 30 years of experience in product development effectively tailoring novel chemistries to targeted applications. He invented the novel photochemistrywhich forms the NVS Therapy.
Kevin Warner, Ph.D.
Vice President, Pharmaceutical Development
Dr. Kevin Warner joined Alucent Biomedical from Allergan, Inc. where he held roles of increasing responsibility in product development, including serving most recently as the director of small molecule development where he lead formulation development activities in support of clinical studies and commercialization.